Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3684 participants.
Also called NCT06096909
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 3,684 participants
- Registry
-
NCT06096909
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06096909. Randomized; double masking; primary purpose treatment. Start 2023-11-11 (actual); primary completion 2028-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population
- Condition
- Acute Coronary Syndrome
- Condition
- Non ST Segment Elevation Acute Coronary Syndrome
- Condition
- Lipid Lowering, Vascular Inflammation
- Intervention (Drug)
- Tafolecimab
- Intervention (Drug)
- Cholesterol Absorption Inhibitor
- Intervention (Drug)
- Statin
- Lead sponsor
- China National Center for Cardiovascular Diseases
- Collaborator
- Innovent Biologics, Inc.
Record details
- Record id
cardio:ct-nct06096909- Content hash
201ba2b830857f5f1cc451f9c989efefdb5be1489667135249a3c334c884741c